Ann: Neuren receives two new patents , page-2

Here's another very important piece to the puzzle for Neuren.

If you recall, a while back I highlighted this passage below from the 2012 CEO AGM presentation

We have worked very hard to ensure that our intellectual property rights are robust and well-protected. And they are. We now have issued patents for composition of matter, oral formulation and broad utility claims as well as a number of pending patent applications. These will not only protect our rights, they will enhance the potential value of the NNZ-2566 franchise in partnering negotiations.

I think the last sentence in the passage above is worth revisiting.

How exactly will this enhance the potential value of the NNZ-2566 franchise in partnering negotiations?

1. A significant consideration in partnering discussions is the strength of the IP portfolio.

2. The broader and more robust the IP protection is, the more valuable the license is.

3. Most potential partners will want to license all rights to the molecule and a strong IP position protects them and Neuren now and in the future as things evolve.

What do we now know about NNZ-2566:

* Oral formulation and the potential uses of NNZ-2566 have expanded well beyond its initial therapeutic target in TBI to include a wider range of conditions.

* These areas represent extremely important areas of unmet medical need.

* They also represent significant opportunities for partnerships and commercialization.

The two passages worth highlighting from today's announcement are;

Notably, both new patents relate to treatment of chronic conditions with oral forms of the molecules.

and...

The first covers oral formulations of NNZ-2566 and the second covers use of NNZ-2591 for the treatment of peripheral neuropathy.

Note: Neuren recently entered into a new CRADA with the Neurosciences group at WRAIR to assess the the effects of orally administered NNZ-2591 on mTOR (a key molecular pathway involved in neuroplasticity and neurite outgrowth that plays a significant role in Rett and Fragile X Syndromes) as well as the Army identifyng the pathways which are regulated by NNZ-2591 including neuroinflammatory cytokines and pro- and anti-apoptopic genes. Not to mention FraX-CVI will also be testing NNZ-2591 in the same fmr1 mouse model of Fragile X Syndrome in which Neuren tested NNZ-2566 and you can see how this is all progressing as planned.

What all this means is that it will inform Neuren about what indications to pursue next and how to position the molecule/s with respect to commercialization.

CEO Larry Glass, then goes on to quote;

As Neuren expands its emphasis on development of therapies for chronic neurological disorders, these patents will further enhance the commercial value of Neuren's drug pipeline.

Onwards and upwards!

Regards,
Tony